p.96 抽出テキスト

2000; 343: 16-22. PMID: 10882764 654. Chiuve SE, Fung TT, Rexrode KM, et al. Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. JAMA 2011; 306: 62-69. PMID: 21730242 655. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343: d6898. PMID: 22115901 656. Fox CS, Golden SH, Anderson C, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care 2015; 38: 1777-1803. PMID: 26246459 657. Iso H, Date C, Yamamoto A, et al. JACC Study Group. Smoking cessation and mortality from cardiovascular disease among Japanese men and women: The JACC Study. Am J Epidemiol 2005; 161: 170- 179. PMID: 15632267 658. Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update 2011; 17: 589- 604. PMID: 21747128 659. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995; 38: 199-210. PMID: 7494882 660. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333. PMID: 12117397 661. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015: CD002229. PMID: 25754617 662. Hodis HN, Mack WJ, Henderson VW, et al. ELITE Research Group. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med 2016; 374: 1221-1231. PMID: 27028912 663. 日本産科婦人科学会,日本女性医学学会.ホルモン補充療法ガイドライン2017年版.日本産科婦人科学会 2017. 664. Løkkegaard E, Andreasen AH, Jacobsen RK, et al. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008; 29: 2660-2668. PMID: 18826989 665. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019; 364: k4810. PMID: 30626577 666. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103-111. PMID: 17333341 667. 日本女性医学学会.女性の動脈硬化性疾患発症予防のための管理指針 2018年度版.診断と治療社 2018. 668. Mabuchi H, Koizumi J, Shimizu M, et al. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989; 79: 225-232. PMID: 2914343 669. Ohmura H, Fukushima Y, Mizuno A, et al. Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome: Multicenter Registration Study in Japan. Int Heart J 2017; 58: 88-94. PMID: 28123161 670. Harada-Shiba M, Ako J, Arai H, et al. Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study. Atherosclerosis 2018; 277: 362- 368. PMID: 30270072 671. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478-3490. PMID: 23956253 672. Harada-Shiba M, Sugisawa T, Makino H, et al. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2010; 17: 667-674. PMID: 20534948 673. Mabuchi H. Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan. J Atheroscler Thromb 2017; 24: 189-207. PMID: 28179607 674. Ohta N, Hori M, Takahashi A, et al. Proprotein convertase subtilisin/ kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. J Clin Lipidol 2016; 10: 547-555. PMID: 27206942 675. Mabuchi H, Nohara A, Noguchi T, et al. Hokuriku FH Study Group. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis 2011; 214: 404-407. PMID: 21146822 676. Tada H, Hori M, Matsuki K, et al. Achilles Tendon Thickness As-

sessed by X-ray Predicting a Pathogenic Mutation in Familial Hyper- cholesterolemia Gene. J Atheroscler Thromb 2022; 29: 816-824. PMID: 34193720 677. Michikura M, Ogura M, Yamamoto M, et al. Achilles Tendon Ultra-

sonography for Diagnosis of Familial Hypercholesterolemia Among Japanese Subjects. Circ J 2017; 81: 1879-1885. PMID: 28652530 678. 日本超音波医学会・日本動脈硬化学会合同用語診断基準委員会,アキレス腱計測標準化小委員会.成人家族性高コレステロール血症スクリーニングに用いる「超音波法によるアキレス腱厚測定」の標準的評価法(2018年7月22日公示). 679. 日本小児科学会・日本動脈硬化学会合同小児家族性高コレステロール血症診療ガイドライン作成ワーキンググループ.小児家族性高コレステロール血症診療ガイドライン 2022.https://www.j-athero. org/jp/wp-content/uploads/publications/pdf/FH_G_P2022.pdf 680. Tada H, Nomura A, Ogura M, et al. Diagnosis and Management of Sitosterolemia 2021. J Atheroscler Thromb 2021; 28: 791-801. PMID: 33907061 681. Koyama S, Sekijima Y, Ogura M, et al. Cerebrotendinous Xanthomatosis: Molecular pathogenesis, clinical spectrum, diagnosis, and disease-modifying treatments. J Atheroscler Thromb 2021; 28: 905-925. PMID: 33967188 682. Li F, Zhang H. Lysosomal acid lipase in lipid metabolism and beyond. Arterioscler Thromb Vasc Biol 2019; 39: 850-856. PMID: 30866656 683. Raal FJ, Stein EA, Dufour R, et al. RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385: 331-340. PMID: 25282519 684. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015; 36: 2996-3003. PMID: 26330422 685. Qian LJ, Gao Y, Zhang YM, et al. Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Sci Rep 2017; 7: 238. PMID: 28331223 686. Uauy R, Vega GL, Grundy SM, et al. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: Lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr 1988; 113: 387-392. PMID: 3397806 687. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013; 128: 2113-2120. PMID: 24014831 688. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011; 124: 2202-2207. PMID: 21986285 689. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356: 148-156. PMID: 17215532 690. Harada-Shiba M, Ikewaki K, Nohara A, et al. Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb 2017; 24: 402-411. PMID: 28154305 691. Ogura M, Makino H, Kamiya C, et al. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. Atherosclerosis 2016; 254: 179-183. PMID: 27755983 692. 日本腎臓学会.エビデンスに基づくCKD診療ガイドライン2018.東京医学社 2018. 693. 厚生労働省.腎疾患対策検討会報告書~腎疾患対策の更なる推進を目指して~ (平成30年7月).https://www.mhlw.go.jp/stf/ shingi2/0000172968_00002.html 694. Tanaka K, Watanabe T, Takeuchi A, et al. CKD-JAC Investigators. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int 2017; 91: 227-234. PMID: 27884399 695. Kadowaki T, Maegawa H, Watada H, et al. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. Diabetes Obes Metab 2022; 24: 2283-2296. PMID: 35929483 696. 花房規男,阿部雅紀,常喜信彦,他.わが国の慢性透析療法の現況(2020年12月31日現在).透析会誌 2021; 54: 611-657. 697. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982- 992. PMID: 19339088 698. Horio M, Imai E, Yasuda Y, et al. Modification of the CKD epidemi-

ology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 2010; 56: 32-38. PMID: 20416999